Complement takes its Toll: an inflammatory crosstalk between Toll-like receptors and the receptors for the complement anaphylatoxin C5a
- PMID: 22150483
- DOI: 10.1111/j.1365-2044.2011.07011.x
Complement takes its Toll: an inflammatory crosstalk between Toll-like receptors and the receptors for the complement anaphylatoxin C5a
Abstract
The innate immune system is responsible for a rapid inflammatory response to pathogens that is essential for the clearance of infections. Although this response is vital, it is nonetheless potentially harmful, and dysregulated inflammation is a feature of many disease states. Thus, the mechanisms that regulate the release of soluble mediators of inflammation are an active focus of investigation. The activation by infections of two key components of the innate immune system, the Toll-like receptors (TLRs) and complement, leading to the release of soluble mediators of inflammation, is critical to microbial killing and clearance. Both TLRs and complement are independently capable of triggering pro-inflammatory responses, but their synergistic interaction resulting from a substantial crosstalk markedly amplifies those responses and may contribute to the pathophysiology of diseases such as sepsis.
Anaesthesia © 2011 The Association of Anaesthetists of Great Britain and Ireland.
References
-
- Kumar H, Kawai T, Akira S. Toll-like receptors and innate immunity. Biochemical and Biophysical Research Communications 2009; 388: 621-5.
-
- Ehrnthaller C, Ignatius A, Gebhard F, Huber-Lang M. New insights of an old defense system: structure, function, and clinical relevance of the complement system. Molecular Medicine 2011; 17: 317-20.
-
- Montz H, Koch KC, Zierz R, Gotze O. The role of C5a in interleukin-6 production induced by lipopolysaccharide or interleukin-1. Immunology 1991; 74: 373-9.
-
- Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nature Medicine 2007; 13: 552-9.
-
- Mollnes TE, Christiansen D, Brekke OL, Espevik T. Hypothesis: combined inhibition of complement and CD14 as treatment regimen to attenuate the inflammatory response. Advances in Experimental Medicine and Biology 2008; 632: 253-63.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources